Table 1.
Demographic and Clinical Characteristics of the Prepectoral and Subpectoral Cohorts
| Characteristic | Prepectoral (N = 25)* | Subpectoral (N = 25)* | P † |
|---|---|---|---|
| Age | 44 (7) | 48 (10) | 0.2 |
| Diabetes mellitus | 0 (0%) | 1 (4.0%) | — |
| BMI | 26.0 (4.7) | 26.4 (6.1) | 0.8 |
| Weight class by BMI | 0.3 | ||
| Normal weight (BMI <25) | 13 (52%) | 15 (60%) | |
| Overweight (BMI 25.0–29.9) | 8 (32%) | 3 (12%) | |
| WHO obesity class 1 (30–34.9) | 3 (12%) | 4 (16%) | |
| WHO obesity class 2 (35–39.9) | 1 (4.0%) | 3 (12%) | |
| Smoking status | 0.6 | ||
| Never | 20 (80%) | 19 (76%) | |
| Current | 0 (0%) | 2 (8.0%) | |
| Former | 5 (20%) | 4 (16%) | |
| History of ipsilateral breast surgery | 0.7 | ||
| Yes | 2 (8.0%) | 4 (16%) | |
| No | 23 (92%) | 21 (84%) | |
| Neoadjuvant chemotherapy | 0.3 | ||
| Yes | 13 (52%) | 9 (36%) | |
| No | 12 (48%) | 16 (64%) | |
| Neoadjuvant endocrine therapy | — | ||
| Yes | 2 (8%) | 1 (4%) | |
| No | 23 (92%) | 24 (96%) | |
| Neoadjuvant anti-Her2 therapy | — | ||
| Yes | 22 (88%) | 22 (88%) | |
| No | 3 (12%) | 3 (12%) | |
| Preoperative clinical stage (AJCC) | 0.6 | ||
| Stage 0 | 1 (4%) | 3 (12%) | |
| Stage I | 10 (40%) | 9 (36%) | |
| Stage II | 11 (44%) | 12 (48%) | |
| Stage III | 3 (12.%) | 1 (4%) | |
| Pathologic stage (AJCC) | 0.3 | ||
| Stage 0 | 3 (12%) | 1 (4.0%) | |
| Stage I | 4 (16%) | 3 (12%) | |
| Stage II | 10 (40%) | 17 (68%) | |
| Stage III | 8 (32%) | 4 (16%) | |
| Tumor type | 0.6 | ||
| Invasive ductal | 15 (60%) | 13 (52%) | |
| Invasive lobular | 4 (16%) | 7 (28%) | |
| Invasive carcinoma with ductal and lobular features | 6 (24%) | 5 (20%) | |
| Ipsilateral mastectomy specimen weight (in grams) | 643 (352) | 616 (435) | 0.8 |
No P value reported when data insufficient to carry out a statistical test.
*
Mean (SD); n (%).
†
Welch Two Sample t test; Fisher exact test; Pearson chi-squared test.
BMI, body mass index; WHO, World Health Organization; AJCC, American Joint Committee on Cancer.